home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.170 +0.200 (+6.73%)

Official Closing Price Updated: 4:15 PM EDT, May 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

2 Reasons to Buy Recursion Pharmaceuticals, and 1 Reason to Sell ↗

October 31, 2023

Pioneering businesses tend to carry big risks, but also the potential for big rewards.

Via The Motley Fool

3 Extra-Speculative Stocks That Could Make You Very, Very Rich ↗

October 26, 2023

Speculative stocks are a growth investor's dream—potential for untold riches, if you can find the stocks that will survive.

Via InvestorPlace

2 Risky Stocks With Massive Potential ↗

October 17, 2023

Neither is doing well this year.

Via The Motley Fool

1 Artificial Intelligence Stock to Buy Hand Over Fist in October and 1 to Avoid ↗

October 13, 2023

One of these players could win in AI -- and in the healthcare market, in general.

Via The Motley Fool

Topics Artificial Intelligence

Is Recursion Pharmaceuticals Stock a Buy Now? ↗

October 11, 2023

The company has grabbed plenty of headlines recently.

Via The Motley Fool

2 Cathie Wood Stocks I'm Bullish On ↗

October 05, 2023

These two next-gen biotechs could be outstanding buys for patient investors.

Via The Motley Fool

Is Recursion Pharmaceuticals Stock a Buy? ↗

September 30, 2023

This small-cap stock hopes to revolutionize drug discovery with the help of AI.

Via The Motley Fool

2 AI Stocks That Aren't Worth the Hype ↗

October 04, 2023

Even if you're bullish on AI, you may want to think twice about buying shares of these two companies.

Via The Motley Fool

Topics Artificial Intelligence

Cathie Wood's Ark Invest Sells Nearly $4M Worth Of NVIDIA Shares — Does It Herald Shift To Undervalued AI Gems? ↗

October 02, 2023

On Monday, Cathie Wood-led Ark Invest made a notable move by selling nearly $4 million worth of NVIDIA Corp (NASDAQ:NVDA) shares. This ...

Via Benzinga

Topics Artificial Intelligence

2 Cathie Wood Stocks That Could Deliver Exponential Returns ↗

October 02, 2023

These two cutting-edge healthcare companies could be significantly undervalued right now.

Via The Motley Fool

AI Investing: 12 Possible Ways To Maximize Your Returns ↗

September 23, 2023

It all comes down to playing it smart and doing your research and to help you with that we present 12 micro/small cap AI&R stocks with descriptions of their businesses and their price-to-sales ratios,...

Via Talk Markets

Topics Artificial Intelligence

Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend ↗

September 22, 2023

Ginkgo Bioworks, Recursion Pharmaceutical, and Eli Lilly are cashing in on the AI-Biotech trend of tomorrow using the big data of today.

Via InvestorPlace

3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too ↗

September 22, 2023

Cathie Wood is loading up on these healthcare stocks.

Via The Motley Fool

Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics ↗

September 15, 2023

They're both liable to grow by a lot, but one of them is a safer bet in the near term.

Via The Motley Fool

3 AI Drug Discovery Stocks to Watch ↗

September 15, 2023

The high cost of developing drugs makes the use of artificial intelligence a natural fit for pharmaceutical companies.

Via The Motley Fool

Topics Artificial Intelligence

2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street ↗

September 12, 2023

Find out why analysts have such high expectations for these stocks.

Via The Motley Fool

AI Integration In Biotech & Pharma: Companies Positioned To Benefit ↗

September 11, 2023

The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care....

Via Benzinga

Topics Artificial Intelligence

Where Will Recursion Pharmaceuticals Be in 3 Years? ↗

September 11, 2023

This biotech could still be a long way from having a drug on the market in 2026.

Via The Motley Fool

2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street ↗

September 06, 2023

Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months.

Via The Motley Fool

3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains ↗

September 05, 2023

These biotech stocks to buy and hold offer tremendous upside blending long-term potential with healthcare advances.

Via InvestorPlace

Recursion to Participate in Upcoming Investor Conferences

September 05, 2023

From Recursion Pharmaceuticals

Via GlobeNewswire

Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection

September 05, 2023

REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent...

From Recursion Pharmaceuticals

Via GlobeNewswire

Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again ↗

August 30, 2023

The famous growth investor has been making some interesting stock moves lately.

Via The Motley Fool

Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe ↗

August 25, 2023

Both businesses have a lot to prove.

Via The Motley Fool

Topics Artificial Intelligence

Cathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI Surge ↗

August 24, 2023

Via Benzinga

Topics Artificial Intelligence

Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks ↗

August 24, 2023

The Ark Invest CEO continues to trim Shopify holdings to fund some big purchases.

Via The Motley Fool

3 Clever Tricks to Find Winning Biotech Stocks ↗

August 24, 2023

You'll need to dig into company details, but the effort is worthwhile.

Via The Motley Fool

AI Bubble Stocks Deflating, Down 14% So Far In August ↗

August 23, 2023

13 artificial intelligence and related stocks have dramatically outpaced the sector in general since the AI&R bubble began to inflate at the end of April. MTD, however, they have declined 13.6%, on...

Via Talk Markets

Topics Artificial Intelligence

Cathie Wood Mops Up $8.1M Worth Of Zoom Stock After Q2 Earnings Beat, Sells Nvidia Shares In Excess Of $1M ↗

August 22, 2023

Via Benzinga

Topics Earnings

Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Instead ↗

August 21, 2023

Via Benzinga

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com